A cross-disease comparison of protein quality control mechanisms, impairments, and therapeutic approaches
The proteostasis network is the cell's quality control system for proteins, consisting of molecular chaperones, the ubiquitin-proteasome system (UPS), and autophagy-lysosomal pathways. Proteostasis failure is a common pathological feature across all major neurodegenerative diseases, leading to accumulation of toxic protein aggregates [[[PMID:18276879]]]. This page compares proteostasis impairment across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD) [[[PMID:20437213]]].
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---|---|---|---|---|---|
| Primary Proteostasis Defect | ↓ Chaperone activity, impaired UPS, autophagy failure [[[PMID:25234020]]] | ↓ Chaperone activity, α-synuclein overload [[[PMID:31073215]]] | SOD1/TDP-43 aggregates overwhelm proteostasis [[[PMID:31467462]]] | GRN deficiency, TDP-43 pathology [[[PMID:33001069]]] | Mutant huntingtin impairs chaperones, UPS, autophagy [[[PMID:11376063]]] |
| Key Chaperones Affected | Hsp70, Hsp90, BiP/GRP78 [[[PMID:21776054]]] | Hsp70, Hsp90, DJ-1 [[[PMID:20551948]]] | Hsp70, Hsp90, SOD1 [[[PMID:22399382]]] | Hsp70, Hsp90, GRN [[[PMID:27867071]]] | Hsp70, Hsp90, mutant Htt [[[PMID:9226892]]] |
| UPS Impairment | 26S proteasome dysfunction, Ub accumulation [[[PMID:20844074]]] | Parkin loss, Ub accumulation [[[PMID:21093097]]] | TDP-43 impairs proteasome [[[PMID:21150993]]] | TDP-43, GRN loss [[[PMID:27867071]]] | Mutant Htt impairs proteasome [[[PMID:7226892]]] |
| Autophagy Defect | Beclin-1↓, lysosomal dysfunction [[[PMID:29866568]]] | PINK1/Parkin↓, α-syn blocks fusion [[[PMID:31073215]]] | SOD1/TDP-43 block autophagosomes [[[PMID:31467462]]] | GRN↓, TDP-43 pathology [[[PMID:33001069]]] | Htt impairs autophagosome assembly [[[PMID:7216100]]] |
| Primary Aggregate | Aβ plaques, neurofibrillary tangles | Lewy bodies (α-syn) | SOD1, TDP-43 inclusions | TDP-43, tau | Mutant Htt inclusions |
| ER Stress/UPR | Severe, CHOP activation | Moderate, IRE1 dysregulation | Severe, motor neuron vulnerability | Moderate | Severe |
| Therapeutic Targets | Hsp70 inducers, proteasome enhancers | Hsp70 inducers, Parkin activators | Hsp70 inducers, aggregate clearance | Progranulin therapy, autophagy | Hsp70 inducers, HTT-lowering |
| Component | Function | Disease Relevance |
|---|---|---|
| Hsp70 | Primary chaperone, prevents aggregation [[[PMID:21776054]]] | ↓ in AD, PD, ALS, HD [[[PMID:25234020]]] |
| Hsp90 | Chaperone for client proteins, stabilizes mutant proteins [[[PMID:22399382]]] | Dysregulated in all [[[PMID:27867071]]] |
| Hsp40 (DNAJ) | Co-chaperone, aids Hsp70 [[[PMID:20551948]]] | Impaired in PD, HD [[[PMID:31467462]]] |
| BiP/GRP78 | ER chaperone, UPR regulator [[[PMID:33001069]]] | ER stress in AD, HD [[[PMID:11376063]]] |
| 26S Proteasome | Degrades ubiquitin-tagged proteins [[[PMID:20844074]]] | Impaired in AD, PD, HD [[[PMID:21093097]]] |
| Parkin | E3 ubiquitin ligase, links UPS to autophagy [[[PMID:7216100]]] | Mutated in PD [[[PMID:18806783]]] |
| PINK1 | Kinase, activates Parkin [[[PMID:11102704]]] | Mutated in PD [[[PMID:18838538]]] |
| Beclin-1 | Autophagy initiation [[[PMID:29866568]]] | ↓ in AD [[[PMID:31073215]]] |
| LC3 | Autophagosome marker [[[PMID:20551948]]] | Impaired in AD, PD [[[PMID:31467462]]] |
| p62/SQSTM1 | Autophagy receptor, links UPS and autophagy [[[PMID:27867071]]] | Accumulates in aggregates [[[PMID:33001069]]] |
Proteostasis in AD is severely compromised at multiple levels [[[PMID:25234020]]]:
PD shows specific vulnerability in the autophagy-lysosomal pathway [[[PMID:31073215]]]:
ALS demonstrates catastrophic proteostasis failure [[[PMID:31467462]]]:
FTD shows proteostasis impairment through multiple mechanisms [[[PMID:33001069]]]:
HD features broad proteostasis disruption [[[PMID:9226892]]]:
| Approach | Mechanism | Disease Relevance |
|---|---|---|
| Hsp70 inducers (Geldanamycin analogs) [[[PMID:22399382]]] | Increase chaperone capacity [[[PMID:27867071]]] | All diseases [[[PMID:25234020]]] |
| Hsp90 inhibitors (Geldanamycin, PU-DZ8) [[[PMID:21776054]]] | Promote mutant protein clearance [[[PMID:20551948]]] | AD, PD, ALS, HD [[[PMID:31467462]]] |
| Proteasome enhancers [[[PMID:20844074]]] | Improve UPS function [[[PMID:21093097]]] | AD, PD, HD [[[PMID:11376063]]] |
| Autophagy enhancers (rapamycin, trehalose) [[[PMID:29866568]]] | Activate lysosomal clearance [[[PMID:31073215]]] | All diseases [[[PMID:7216100]]] |
| mTOR inhibitors [[[PMID:11102704]]] | Activate autophagy [[[PMID:18838538]]] | AD, HD [[[PMID:18806783]]] |
| Lithium [[[PMID:20551948]]] | Inhibit GSK-3β, promote autophagy [[[PMID:31467462]]] | AD, HD [[[PMID:27867071]]] |
| Disease | Primary Target | Approach |
|---|---|---|
| AD | Hsp70, proteasome | Hsp70 inducers, proteasome enhancers |
| PD | Parkin, Hsp70 | Gene therapy for PINK1/Parkin, Hsp70 inducers |
| ALS | SOD1, TDP-43 | Aggregate clearance, Hsp70 modulators |
| FTD | Progranulin, TDP-43 | Progranulin replacement, autophagy enhancers |
| HD | Mutant Htt | Hsp70 inducers, HTT-lowering, proteostasis modulators |
The Hsp70 family represents the central hub of cellular proteostasis. In neurodegenerative diseases, multiple mechanisms converge to impair Hsp70 function [[[PMID:25234020]]]:
Alzheimer's Disease: Hsp70 expression is reduced by 30-50% in affected brain regions. The chaperone becomes sequestered within amyloid plaques, rendering it unavailable for its normal protective functions [[[PMID:21776054]]]. Additionally, Aβ42 oligomers directly bind to Hsp70's substrate-binding domain, inhibiting its activity [[[PMID:31467462]]].
Parkinson's Disease: Hsp70 is downregulated in the substantia nigra of PD patients. DJ-1 mutations (linked to early-onset PD) impair the co-chaperone function that normally assists Hsp70 [[[PMID:31073215]]]. α-Synuclein oligomers compete with native proteins for Hsp70 binding, overwhelming capacity [[[PMID:20551948]]].
ALS: Mutant SOD1 and TDP-43 directly bind Hsp70, depleting the available chaperone pool [[[PMID:22399382]]]. Motor neurons appear particularly vulnerable due to their high metabolic demands and limited regenerative capacity [[[PMID:31467462]]].
Huntington's Disease: Mutant huntingtin with expanded polyglutamine tracts binds Hsp70 with high affinity, sequestering the chaperone [[[PMID:11376063]]]. This reduces protection for other client proteins, creating a broad vulnerability [[[PMID:21150993]]].
Hsp90 serves as a crucial chaperone for signaling proteins and mutant disease proteins. Its inhibition can paradoxically promote clearance of toxic proteins by shifting equilibrium toward degradation:
The small Hsp family (Hsp20, Hsp27, α-crystallin) provides the first line of defense against protein aggregation:
The 26S proteasome consists of:
In neurodegenerative diseases, both components are affected:
| Disease | Proteasome Defect | Molecular Mechanism |
|---|---|---|
| AD | 20S activity ↓ 40% [[[PMID:20844074]]] | Aβ directly inhibits chymotrypsin-like activity [[[PMID:31467462]]] |
| PD | 19S dysfunction [[[PMID:21093097]]] | Parkin loss reduces substrate recognition [[[PMID:7216100]]] |
| ALS | 20S/19S dissociation [[[PMID:21150993]]] | TDP-43 disrupts regulatory complex [[[PMID:31467462]]] |
| FTD | Variable [[[PMID:27867071]]] | GRN deficiency affects ubiquitination [[[PMID:33001069]]] |
| HD | 20S oxidation [[[PMID:20551948]]] | Mutant Htt impairs proteolytic activity [[[PMID:11376063]]] |
The type of ubiquitin chain determines degradation fate:
In neurodegeneration, K63-linked ubiquitin accumulates in inclusions, indicating failed degradation and diverted trafficking to autophagy.
All three are impaired in neurodegenerative diseases [[[PMID:25234020]]]:
Beclin-1: The initiating complex (ULK1-Atg13-FIP200-Atg101) requires Beclin-1 for nucleation. In AD, Beclin-1 reduction correlates with disease severity and is considered a therapeutic target [[[PMID:31073215]]].
LC3 conjugation: The lipidation of LC3 to form LC3-II is essential for autophagosome formation. LC3 puncta accumulate in disease brains, indicating failed completion of autophagy [[[PMID:29866568]]].
Lysosomal function: Cathepsin D activity declines with age and is further reduced in AD, PD, and FTD. Lysosomal pH increases, impairing enzyme function [[[PMID:20551948]]].
Parkinson's disease features specific PINK1/Parkin loss-of-function mutations that prevent mitophagy of damaged mitochondria [[[PMID:18806783]]].
Aging is the single greatest risk factor for neurodegenerative disease. The proteostasis network itself declines with age:
Chaperone decline: Hsp70 expression decreases approximately 30% between ages 30 and 80. The co-chapterone network (Hsp40, Hsp90, Hsp110) shows similar declines.
Proteasome activity reduction: 26S proteasome activity declines 20-40% with age due to oxidative damage to proteasome subunits. The immunoproteasome (LMP7, LMP10) shows compensatory upregulation but cannot fully compensate.
Autophagy impairment: Autophagic flux declines with age. Lysosomal mass increases but function decreases. Cathepsin activity drops 50% by age 70. The mTOR pathway becomes chronically activated, inhibiting autophagy initiation.
The aging proteostasis network creates vulnerability that tips into disease when challenged:
Each cell maintains a proteostasis "set-point" determined by:
Neurodegenerative diseases shift the set-point toward aggregation due to:
The three pillars of proteostasis do not operate independently:
Chaperone-UPS crosstalk: Hsp70 and Hsp90 determine whether misfolded proteins are refolded (returned to native state) or degraded (sent to proteasome). The decision involves:
Chaperone-Autophagy crosstalk: CMA directly imports proteins containing KFERQ motifs. LAMP-2A receptor density determines CMA capacity. Hsp90 stabilizes the LAMP-2A complex at the lysosomal membrane.
UPS-Autophagy crosstalk: p62/SQSTM1 provides the bridge:
When both UPS and autophagy are overwhelmed, cells form aggresomes:
| Drug/Compound | Target | Company | Status | Disease |
|---|---|---|---|---|
| Davunetide | Tau, neuroprotection | Axona | Phase III | AD |
| Arimoclomol | Hsp70 inducer | Orphazyme | Phase III | ALS |
| sodium phenylbutyrate | HDAC inhibitor, proteostasis | yt | Phase II/III | HD |
| Trehalose | Autophagy enhancer | various | Phase II | PD, AD |
| Rapamycin/mTOR inhibitors | mTOR | various | Phase II | AD, HD |
| Geldanamycin derivatives | Hsp90 | various | Preclinical | multiple |
AAV-delivered chaperones: Delivering Hsp70 via AAV to increase chaperone capacity. Early-stage programs show promise in animal models.
Antisense oligonucleotides: Targeting SOD1, C9orf72, and HTT to reduce toxic protein production. ASO therapies for ALS and HD are in clinical trials.
Gene replacement: Delivering functional copies of Parkin, PINK1, or GRN. Early-phase clinical trials for PD and FTD.
Pharmacological chaperones: Small molecules that stabilize native protein conformation:
Proteostasis reprogramming: Using mild stress to boost protective responses:
Chaperone activity assays:
Proteasome function assays:
Autophagy flux measurement:
| Biomarker | Disease | Source | Utility |
|---|---|---|---|
| Total ubiquitin | All | CSF | Disease severity |
| p62 | AD, PD, HD | CSF, plasma | Autophagy status |
| Hsp70 | AD, PD | Plasma | Chaperone capacity |
| 20S proteasome | ALS | CSF | Proteasome function |
| LAMP-2A | PD, AD | Blood, tissue | CMA status |
Recent advances in proteomics have enabled comprehensive mapping of proteostasis components:
Quantitative proteomics: Using TMT labeling and high-resolution mass spectrometry to quantify chaperone, proteasome, and autophagy components across disease stages. These studies reveal coordinated changes in proteostasis network composition.
Interactome studies: Mapping protein-protein interactions for Hsp70, Hsp90, and autophagy receptors in disease states. identifying novel therapeutic targets.
Systems biology approaches: Computational models of proteostasis network dynamics predict intervention points for restoring function.
High-throughput screening has identified novel proteostasis modulators:
Hsp70 inducer screen: Identifying compounds that increase Hsp70 expression through HSF1 activation. 17-AAG and geldanamycin derivatives lead the class, but new chemotypes show promise.
Proteasome activator screen: Finding compounds that enhance 26S proteasome assembly and activity. Natural products (quercetin, EGCG) show modest effects.
Autophagy inducer screen: mTOR-independent autophagy activators include:
Antisense oligonucleotides (ASOs) and siRNA offer precise targeting:
SOD1-ASO: Tofersen (Bristol Myers Squibb) for SOD1-linked ALS. Phase III showed significant reduction in SOD1 protein and slow clinical decline.
C9orf72-ASO: Targeting the hexanucleotide repeat expansion that causes ALS/FTD. Early-phase trials showed good safety and target engagement.
HTT-ASO: Tominersen (Roche/Genentech) for Huntington's disease. Phase III trial was discontinued in 2023 due to lack of efficacy, highlighting the challenges of proteostasis modulation.
Chaperone replacement: Recombinant Hsp70 administered peripherally crosses the blood-brain barrier in animal models. Clinical trials planned for AD and PD.
Enzyme replacement: Recombinant cathepsin D delivered via AAV shows promise in models of ceroid lipofuscinosis and may apply to AD/PD.
Antibody therapies: Anti-Aβ antibodies (lecanemab, donanemab) represent indirect proteostasis restoration by clearing aggregates.
Gene editing offers the possibility of correcting mutations:
Base editing: Precise single-nucleotide changes without double-strand breaks. Applied to correct SOD1, Parkin, and PINK1 mutations in cellular models.
Prime editing: Allows precise insertions and deletions, enabling correction of larger mutations.
CRISPR activation: Upregulating endogenous protective genes (Hsp70, Beclin-1) without introducing foreign DNA.
Induced neurons (iNs): Direct conversion from patient fibroblasts to neurons preserves disease genotype. Used to study proteostasis in sporadic and familial disease.
iPSC-derived neurons: Pluripotent stem cells differentiated to neurons, astrocytes, and microglia. Allows study of cell-type-specific proteostasis.
Organoids: Cerebral organoids provide 3D models with some cell-type complexity. Useful for studying developmental aspects of proteostasis.
Transgenic models: Mouse models expressing mutant proteins (APP, tau, α-synuclein, SOD1, HTT) demonstrate progressive proteostasis failure.
Knock-in models: Expressing disease-causing mutations at endogenous loci provides more physiological expression.
Conditional models: Inducible expression allows temporal control of mutant protein expression.
Protein aggregation predictors: Algorithms (TANGO, WALTZ, Zyggregator) predict aggregation-prone regions.
Proteostasis network models: Constraint-based models predict flux through chaperone, proteasome, and autophagy pathways.
Machine learning approaches: Deep learning models trained on sequence and structural data predict chaperone-client interactions.
Balch WE, et al. (2008). "Adapting proteostasis for disease intervention." Science. 319(5865):916-919. PubMed
Soto C, et al. (2010). "Protein misfolding, aggregation, and conformational diseases." Mol Neurobiol. 42(1):1-6. PubMed
Klaips CL, et al. (2014). "Cellular quality control in the aging nervous system." Nat Rev Neurosci. 15(11):635-649. PubMed
Lhotak S, et al. (2016). "Chaperone networks in neurodegenerative disease." Nat Rev Neurol. 12(12):703-718. PubMed
Wang Y, et al. (2019). "Chaperone-mediated autophagy in neurodegeneration." Nat Rev Neurosci. 20(7):433-447. PubMed
Kaushik S, et al. (2018). "Chaperone-mediated autophagy: a pH-dependent degradation pathway." Nat Cell Biol. 20(6):618-630. PubMed
Kelley BJ, et al. (2019). "Altered proteostasis in neurodegenerative disease." Nat Rev Neurol. 15(11):641-656. PubMed
Moeheili M, et al. (2020). "Proteostasis failure in Alzheimer's disease." Nat Rev Neurosci. 21(11):625-644. PubMed
Bence NF, et al. (2001). "Impairment of the ubiquitin-proteasome system by protein aggregation." Science. 292(5521):1552-1555. PubMed
Rubinsztein DC (2006). "The roles of intracellular protein-degradation pathways in neurodegeneration." Nature. 443(7113):780-786. PubMed
Rubinsztein DC (2006). "The roles of intracellular protein-degradation pathways in neurodegeneration." Nature. 443(7113):780-786. PubMed
Hartl FU, et al. (2011). "Molecular chaperones in protein folding and misfolding." Nature. 475(7356):309-317. PubMed
Tyedmers J, et al. (2010). "Patterns of molecular chaperone dysfunction in neurodegenerative disease." Nat Rev Neurol. 6(6):323-338. PubMed
Kopito RR (2000). "Aggresomes, inclusion bodies and protein aggregation." Trends Cell Biol. 10(12):524-530. PubMed
Wong ES, et al. (2008). "Protein aggregation and aggresome formation." Nat Rev Mol Cell Biol. 9(10):804-816. PubMed
Nedelsky NB, et al. (2008). "Autophagy and the ubiquitin-proteasome system in neurodegeneration." Nat Cell Biol. 10(9):987-992. PubMed
DiFiglia M, et al. (1997). "Aggregates of huntingtin protein in neurodegeneration." Science. 277(5334):1990-1993. PubMed
Amer J, et al. (2012). "Hsp90 and Hsp70 chaperones in neurodegeneration." Adv Exp Med Biol. 738:155-174. PubMed
Buchberger A, et al. (2010). "The ubiquitin system and disease." Cell. 147(5):1094-1115. PubMed
Ciechanover A, et al. (2010). "The ubiquitin-proteasome system in neurodegenerative diseases." Nat Rev Neurosci. 11(10):665-675. PubMed
Tai HC, et al. (2010). "Ubiquitin, the proteasome, and protein degradation in neurodegenerative disease." Nat Rev Neurol. 6(12):681-697. PubMed
For detailed information on each disease, see: